Clinical Trial Update: Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors [NA]

View source ↗

Summary

This clinical trial update notes the completion of a study evaluating PSMA PET/CT as an imaging biomarker in metastatic castration-resistant prostate cancer and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Solid Tumors

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors | NA | Status: COMPLETED